

Cortical thickness and sub-cortical volumes in narcolepsy

type 1: A brain-wide MRI case-control study

Authors: Hilde T. Juvodden¹, Dag Alnæs^{2,3}, Ingrid Agartz^{4,5,6}, Ole A. Andreassen^{2,6},
Andres Server⁷, Per M. Thorsby^{8,9}, Lars T. Westlye^{2,6,10}, Stine Knudsen-Heier^{1,9}

Author affiliations:

1 Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias (NevSom), Department of Rare Disorders, Oslo University Hospital, Ullevål, Norway

2 NORMENT Centre, Division of Mental Health and Addiction, University of Oslo and Oslo University Hospital, Norway

3 Kristiania University College, Oslo, Norway

4 Norwegian Centre for Mental Disorders Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway

5 Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway

6 K.G. Jebsen Centre for Neurodevelopmental Disorders, University of Oslo, Norway

7 Department of Radiology and Nuclear medicine, Oslo University Hospital, Oslo, Norway

8 Hormone Laboratory, Department of Medical Biochemistry, Biochemical Endocrinology and Metabolism Research Group, Oslo University Hospital, Aker, Norway

9 Department of clinical medicine, University of Oslo, Norway

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

10 Department of Psychology, University of Oslo, Norway

Correspondence to: Hilde T. Juvodden, Oslo University Hospital, Ullevål Hospital,
Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias
(NevSom), PO Box 4956 Nydalen, NO-0424 OSLO, Norway.

Telephone number: +47 916 11 528. Email: hilde.juvodden@gmail.com

Abstract

Study Objectives: Narcolepsy type 1 (NT1) is associated with loss of functioning hypocretin-producing neurons and an increase in histaminergic neuron numbers in the hypothalamus. These cell groups have largely overlapping projections to other brain regions, and may be associated with distributed patterns of secondary affection of sub-cortical and cortical gray matter. We performed a case-control comparison of MRI-based global and sub-cortical volume and cortical thickness in NT1 patients compared with healthy controls.

Methods: We processed T1-weighted brain MRI data from 54 NT1 patients (51 with confirmed hypocretin-deficiency; 39 females, mean age 21.8 ± 11.0 years) and 114 healthy controls (77 females, mean age 23.2 ± 9.0 years) using FreeSurfer. Group differences among three global and 10 sub-cortical volume measures and 34 cortical thickness measures for bilateral brain regions were tested using general linear models with permutation testing. We corrected for multiple testing with the Benjamini-Hochberg procedure with the false discovery rate at 5%.

Results: NT1 patients had significantly thinner brain cortex bilaterally in the temporal poles (*Cohen's* $d=0.68$, $p=0.00080$), entorhinal cortex ($d=0.60$, $p=0.0018$) and superior temporal gyrus ($d=0.60$, $p=0.0020$) compared to healthy controls. The analysis revealed no significant group differences for sub-cortical volumes.

Conclusions: NT1 patients have significantly thinner cortex in temporal brain regions compared to controls. We speculate that this effect can be partly attributed to the hypothalamic neuronal change in NT1, including loss of function of the widely projecting hypocretin-producing neurons and secondary effects of the abnormal sleep-wake pattern in NT1.

Keywords: narcolepsy; MRI; T1; entorhinal; superior temporal gyrus; temporal pole

Statement of Significance

Narcolepsy type 1 (NT1) patients have loss/dysfunction of hypocretin-producing neurons and increased histaminergic neurons number – cell groups which project widely to other brain regions. It is therefore plausible that other brain regions may be affected by the hypothalamic changes in NT1 patients. Compared to healthy controls, we show that NT1 patients have thinner cortex bilaterally in the entorhinal cortex, temporal poles and superior temporal gyrus (STG). STG play a role in hallucinations and entorhinal cortex and temporal poles in memory functions. Thinner cortex in these regions have been implicated in diseases sharing common features with NT1, like schizophrenia and obstructive sleep apnea. Further studies are needed to establish the clinical relevance and investigate possible causal effects using a longitudinal design.

Introduction

Narcolepsy type 1 (NT1) is a neurological sleep disorder characterized by cataplexy, excessive daytime sleepiness and disturbed night sleep, and it is also common for the patients to experience hypnagogic hallucinations and sleep paralysis. [1] The incidence of narcolepsy increased by 10-fold after the H1N1 mass vaccination in 2009/2010 in Norway and several other countries. [2, 3]

NT1 patients have a loss/dysfunction of hypocretin-producing neurons in the hypothalamus most likely due to an autoimmune process. [1, 4-6] Hypocretin-deficiency can be measured in the cerebrospinal fluid and used diagnostically. [1] The hypocretin-producing neurons are central in sleep/wake-regulation, they project widely to other brain regions, and the loss of these neurons have been shown to disrupt the functioning of multiple frontal, limbic, diencephalic and brainstem networks. [1, 7] In addition, an increase in the numbers of histaminergic neurons of the hypothalamus have been detected in several post-mortem studies, which has been proposed to represent a compensatory mechanism, although this is controversial as it has also been speculated if it plays a role in disease development. [1, 8, 9] The histaminergic neurons and the hypocretin-producing neurons can be found adjacent to each other in the hypothalamus and their projections to other brain regions also largely overlap. [10] As increased knowledge of the distributed nature of brain structural affection in NT1 can give insight into the disease mechanisms, possible consequences due to an abnormal sleep-wake pattern and also have potential as an MRI-based biomarker, which has been studied by several groups. However, previous structural MRI studies investigating brain volume have reported conflicting results when comparing narcolepsy patients to controls, [11-26] possibly due to relatively small and heterogenous patient samples. Therefore, in this largest study to date, we used brain MRI to obtain three global and 10 sub-cortical volume

measures and 34 cortical thickness measures covering the full brain from our homogenous and well-characterized patient sample of hypocretin deficient NT1 patients.

Materials and Methods

Participants

We recruited 70 suspected NT1 patients from June 2015 to April 2017 with disease onset after the 2009/2010 H1N1-pandemic and vaccination campaign. The patients were a part of a national post-H1N1 narcolepsy follow-up project initiated by the Norwegian Ministry of Health and Care Services. Patient and their families were referred for narcolepsy disease education and counseling courses at the Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias (NevSom) and were invited to also participate in the scientific part of the project during their stay at our center. Written informed consent was provided by all participants before inclusion (parents signed for children <16 years of age) and the Norwegian regional committees for medical and health research ethics (REK) approved the study.

Exclusion criteria for patients were severe somatic, neurological or psychiatric disorders, metallic implants, neuroradiological findings requiring a clinical follow-up and previous head injury with loss of consciousness for 10 minutes or 30 minutes amnesia.

Two patients were excluded due to severe psychiatric/neurological disorders, two patients were excluded due to not fulfilling the NT1 ICSD-3 diagnostic criteria, [27] four patients were excluded due to braces leading to bad quality MRI data and eight patients due to excessive head movement during MRI. The remaining 54 patients were included in the analysis. The clinical and demographic information are summarized in Table 1. Five patients had Apnea Hypopnea Index (AHI) ≥ 5 and the average AHI for the patients were 3.3 ± 9.1 . Patients were requested to pause all narcolepsy medication and other medication affecting

sleep/wake for 14 days prior to inclusion, however three patients were unable to do this completely. One patient only paused Venlafaxine for 7 days prior to inclusion due to severe cataplexy; and due to comorbidity two other patients continued to use Fluoxetine and Catapresan, respectively.

Additional information obtained during or after study inclusion revealed the disease onset to be prior to the H1N1-vaccination campaign for three patients in the H1N1-vaccinated group. These three patients had typical NT1 phenotypes with cataplexy, HLA-DQB1*06:02-positivity and hypocretin-deficiency and hence remained included in the study. The H1N1-vaccination information was obtained from the official Norwegian Immunisation Registry (SYSVAK). Two patients in the H1N1-vaccinated group were not registered in SYSVAK but reported having been H1N1-vaccinated at their workplace.

Comorbidities are common in NT1 patients [4] and we therefore included the following comorbidities in the main analysis: migraine (n=6), Asperger syndrome (n=2), attention-deficit hyperactivity disorder (ADHD; n=1), anxiety (n=1), depression (n=1), Tourette syndrome (n=1), kidney disease (n=1), type 2 diabetes (n=1), hypothyroidism (n=1) and premature birth without severe long-term complications (n=1). There were in total 14 patients with these comorbidities as some patients had more than one comorbidity.

Healthy controls (n=114) were included from ongoing studies coordinated by the Norwegian Centre for Mental Disorders Research (NORMENT). The controls were scanned with the same MRI scanner and protocol as the NT1 patients. Exclusion criteria for healthy controls were somatic, neurological or psychiatric disease, severe psychiatric family history, metal implants, previous head injury with 30 minutes amnesia or loss of consciousness for 10 minutes, and neuroradiological findings indicating ongoing or previous disease or abnormalities.

Narcolepsy diagnosis

An experienced neurologist and somnologist (S.K.H.) evaluated the patients clinical and sleep parameters and CSF hypocretin-1 measurements and verified their NT1 diagnosis based on the ICSD-3 criteria. [27] In addition to semi-structured interviews, including a Norwegian translation of the validated Stanford Sleep Questionnaire [28] patients underwent clinical assessments including a neurological examination, human leukocyte antigen (HLA)-typing, routine blood parameter sampling, actigraphy, polysomnography (PSG) and a multiple sleep latency test (MSLT). Spinal taps for the patients were done at their local hospitals prior to or after inclusion. The CSF hypocretin-1 levels were analyzed at the Hormone Laboratory of Oslo University Hospital using a slight modification to the method of Phoenix Pharmaceutical St. Joseph, MO as previously published. [29, 30]

Polysomnography recordings

Most patients were evaluated with 10-14 days of actigraphy (Philips Actiwatch, Respironics Inc., Murrysville, PA, USA) prior to their polysomnography and multiple sleep latency test. The polysomnography recordings were obtained with the SOMNOmedics system (SOMNOmedics GmbH, Randersacker, Germany) with the electrodes F3-A2, C3-A2, O1-A2, F4-A1, C4-A1 and O2-A1, vertical and horizontal electro-oculography, surface electromyography of the tibialis anterior and submental muscles, nasal pressure transducer, nasal thermistor, thoracic respiratory effort, oxygen saturation and electrocardiography. Impedance was kept below 10k Ω (preferably 5 Ω). The polysomnography was followed the next day by a 5-nap multiple sleep latency test, were 2-hour intervals separated the naps (30 minutes). The American Academy of Sleep Medicine scoring criteria were used. [27]

MRI acquisition and processing

A General Electric Discovery MR750 3T scanner with a 32-channel head coil were used to obtain the T1-weighted MRI data with the following parameters: Voxel size 1 x 1 x 1 mm; echo time (TE): 3.18 ms; repetition time (TR): 8.16 ms; flip angle: 12°; 188 sagittal slices.

FreeSurfer [31] (v.7.1.0) was used to process the T1-weighted data using the standard recon-all pipeline. FreeSurfer's Euler number [32] was used for quality control. Datasets with Euler number ± 3 standard deviations from the mean were visually inspected. We obtained three global, 10 subcortical volume measures and 34 cortical thickness measures. [33] All measures were then analysed as bilateral. The bilateral volume measures were computed as the average of the right and left hemisphere measurement. The bilateral thickness measures was calculated with the formula: $\text{Bilateral thickness} = ((\text{lh.thickness} * \text{lh.surfacearea}) + (\text{rh.thickness} * \text{rh.surfacearea})) / (\text{lh.surfacearea} + \text{rh.surfacearea})$.

Statistical analysis

We used Permutation Analysis of Linear Models (PALM) [34-36] to test for group differences in volume and thickness. We included age, sex and intracranial volume (ICV) in linear models for regional volume measures, and age and sex in the models for global volume and thickness measures. We performed 5000 permutations, yielding t-statistics, contrast of parameter estimate (COPE)s, two-tailed p-values and Cohen's d. Cohen's d is calculated as $\text{COPE} / \text{square root (variance of the residuals)}$ in PALM. Due to a sibling pair in the patient group, permutations were constrained between these two to control for the lack of independence. We corrected for multiple testing (47 tests - testing group difference in 13 bilateral volume and 34 bilateral thickness measures) with the Benjamini-Hochberg procedure [37] to control the false discovery rate (FDR) at 5%.

Further, for the main models revealing a significant group difference an additional sensitivity analysis was performed, excluding patients with the comorbidities listed above and/or AHI ≥ 5 . This additional analysis included 37 patients (28 females, mean age 21.7 ± 11.9) and 114 controls (77 females, mean age 23.2 ± 9.0).

Data availability

Due to ethical restrictions the data are not publicly available as it could compromise the privacy of the participants, as NT1 is a rare disorder and Norway has a relatively small population.

Results

Cortical thickness

Table 2 summarizes the uncorrected (not corrected for age and sex) mean cortical thickness measures for patients and controls for all the included regions. Permutation testing revealed that patients had thinner cortex bilaterally compared to controls in the temporal poles ($d=0.68$, $p=0.00080$), entorhinal cortex ($d=0.60$, $p=0.0018$), superior temporal gyrus (STG) ($d=0.60$, $p=0.0020$), middle temporal gyrus ($d=0.50$, $p=0.0088$), rostral middle frontal gyrus ($d=0.49$, $p=0.009$), superior frontal gyrus ($d=0.41$, $p=0.029$) and postcentral gyrus ($d=0.38$, $p=0.043$). After FDR correction the bilateral temporal poles, entorhinal cortex and superior temporal gyrus remained significant (Figures 1-2).

Subcortical and global brain volumes

Table 3 summarizes the uncorrected (not corrected for age, sex or ICV) mean cortical and sub-cortical volumes for patients and controls for all the tested regions. Compared to controls, patients showed smaller global cortical volume ($d=0.43$, $p=0.03$) and smaller total gray matter (GM) volume ($d=0.37$, $p=0.0059$). After FDR correction these differences were not significant.

Sensitivity analysis

Sensitivity analyses were performed for the bilateral temporal poles, entorhinal cortex and STG thickness measures, excluding patients with the comorbidities listed above and AHI ≥ 5 . Permutation testing revealed similar results as in the main analysis with thinner cortex bilaterally for patients compared to controls for the temporal poles ($d=0.53$, $p=0.016$), entorhinal cortex ($d=0.54$, $p=0.013$) and STG ($d=0.41$, $p=0.05$).

Discussion

Our main finding was significantly thinner cortex for NT1 patients compared to controls bilaterally in the STG, temporal poles and entorhinal cortex, all located in the temporal lobe. Several previous studies [12, 13, 15, 18, 24] have implicated changes in the STG for narcolepsy patients, but our study is the first to report thinner temporal poles and entorhinal cortex.

The STG is critical for speech perception and injuries to this region lead to extensive deficits in the comprehension of speech. [38] Wernicke's aphasia after damage to the STG is characterized by fluent speech, but severely impaired comprehension. [39] The STG is considered to encode the more complex features of sound than the earlier regions of the

auditory hierarchy and is therefore considered to be a part of the higher-order associative auditory cortex. [38] Smaller STG in schizophrenia patients compared to controls has been reported [40] and a longitudinal study of patients with first-episode schizophrenia suggested a progressive volume reduction of the left posterior STG 1.5 years after the first hospitalization. [41] STG is thought to play a role in auditory hallucinations and thought disorder in schizophrenia, and electrical stimulation of the STG can cause hallucinations. [40] In our study 85 % of the NT1 patients have experienced hypnagogic (at sleep onset) or hypnopompic (on awakening) hallucinations. Likewise, other studies have indicated that up to 80% of NT1 patients experience hypnagogic/hypnopompic hallucinations, but some also report daytime hallucinations not connected to sleep. [42] The hallucinations in NT1 patients are presumed to represent intrusion of REM-sleep into wakefulness and most often the patients are aware that the hallucinations are not real. [42] Unlike schizophrenia patients who often have verbal-auditory hallucinations, multisensory hallucinations dominate for NT1 patients. [42] However, NT1 patients can have more non-verbal auditory hallucinations (footsteps, animal sounds etc.) than schizophrenia patients and there has been cases where the hallucinations in NT1 patients lead to a misdiagnosis of schizophrenia. [1, 42] Only eight of our NT1 patients had not experienced hypnagogic/hypnopompic hallucinations, and the associations between hallucinations and cortical thickness among NT1 patients should be explored in a larger multi-center study to gain enough patients without hallucinations.

The observed group differences might also be attributed to secondary effects due to abnormal sleep-wake patterns. Compared to day-workers reduced STG volume has been reported among shift workers who also reported more sleep disturbances and depressive symptoms. [43] Further, thinner STG has also been reported in patients with obstructive sleep apnea (OSA). [44] In our study, five NT1 patients had $AHI \geq 5$, however these patients were

excluded from the sensitivity analysis which largely supported the results from the main analysis.

Interestingly we also found significantly thinner temporal poles for the patients compared to controls in the present study, which has not been reported previously. The temporal poles are thought to play a role in memory and a new class of face memory cells was reported in a recent study [45] from recordings of the temporal pole in rhesus monkeys. These cells do not respond to faces in general, but to faces that are personally familiar. [45] The temporal pole has also been associated with visual processing of complex objects, naming and word object labeling and autobiographic memory. [46] It has also been revealed that the temporal pole has a role in language and semantic processing, with activation in PET studies during linguistic tasks as for example recall of word lists and story recall. [46] Furthermore, the temporal poles have been associated with socio-emotional processing. [46] An example of this can be seen with a variant of frontotemporal lobar degeneration which gives right temporal pole atrophy and have symptoms like social awkwardness, difficulty in identifying people, loss of insight, loss of empathy, aggressive behavior, irritability, poor emotional regulation and personality changes. [46] In patients with traumatic brain injury impairment of a social problem-solving task was associated with cortical thickness of the temporal pole. [46] A large meta-analysis [47] of 4474 schizophrenia patients and 5098 healthy controls reported a stronger negative correlation between age and cortical thickness in the bilateral temporal poles for the patients than the controls. Further, a longitudinal study [48] of first-episode schizophrenia patients showed smaller GM volume and progressive GM volume decrease in the temporal pole after 1.5 years.

We also found significantly thinner entorhinal cortex in patients compared to controls, which has not previously been reported. The entorhinal cortex is important for episodic memories, which can be defined as the ability to recall what happened in a spatiotemporal

context, [49-51] and input from the entorhinal cortex to the hippocampal formation is a critical part of being able to form these types of memories. [51] The entorhinal cortex is also important for spatial navigation and the forming of universal maps, and in the medial entorhinal cortex spatially modulated cells can be found like the grid cells. [49-51]

The entorhinal cortex has also been implicated in an MRI study of OSA patients, investigating structural MRI changes in relation to cognitive deficits before and after treatment (3 months with continuous positive airway pressure (CPAP)). [52] Before treatment OSA patients exhibited smaller GM volumes compared to controls in several regions including the entorhinal cortex. Entorhinal volume increase after treatment was correlated with improvements in tests for short-term memory and executive functions. [52] The authors speculated that structural and cognitive deficits in OSA patients might be secondary to the hypoxemia, disturbances in autonomic activity or the sleep fragmentation. [52] NT1 patients have problems with maintaining sleep and wakefulness. [1] This leads to sleep fragmentation, which could partly explain our findings and provide a possible link to MRI findings in OSA. As mentioned, five NT1 patients in our study have $AHI \geq 5$, but as they were excluded from the sensitivity analysis, which largely supported the results from the main analysis, it is unlikely that this can explain the group difference.

A recent study compared performance on a visual perceptual learning task before and after naps between 15 NT1 patients, 14 NT2 patients and 7 idiopathic hypersomnia patients . [53] NT1 patients often have naps starting in REM-sleep and then continuing to non-REM-sleep (NREM), and the study found that sleep spindles only were associated with memory consolidation when the naps started with NREM-sleep followed by REM-sleep. [53] However, studies have indicated that possible memory deficits in NT1 patients seem to be limited to specific memory functions and there have been some indications of alterations of

procedural memory with less effective memory consolidation as well as impaired working memory. [54]

Previous structural MRI studies of narcolepsy patients [11-26] have revealed conflicting results involving various brain regions. A review from 2019 [11] including 13 structural MRI studies [12-14, 16-26] on narcolepsy showed that replicated findings (defined as being reported in two or more articles) were reductions of superior frontal gyri, superior and inferior temporal gyri, middle occipital gyri, hypothalamus, amygdala, insula, hippocampus, cingulate cortex, thalamus and nucleus accumbens. However, the authors stated that the replicated findings are controversial due to several issues, including small and heterogeneous patient samples with large variation in age and disease duration, which means that effect of aging, illness and possible compensatory mechanisms are difficult to distinguish.

A meta-analysis [15] of eight voxel-based morphometry (VBM) studies [12-14, 17-20, 24] of narcolepsy patients where the studies either assessed GM concentration [12, 18, 24] or GM volume [13, 14, 17, 19, 20] reported significant GM reductions in patients bilaterally in the hypothalamus, nucleus accumbens, anterior cingulate cortex, thalamus, left mid orbital and rectal gyri, right inferior frontal and superior temporal gyri. However, the authors of the meta-analysis [15] pointed out several limitations as the included studies applied different inclusion and exclusion criteria, heterogeneous patient samples and methodologies.

We investigated MRI based brain structure in a large, homogenous and well-characterized patient sample compared to healthy controls. All participants were assessed in the same scanner using identical MRI sequences. The disease duration was approximately 6 years and 51/54 patients had confirmed hypocretin-deficiency (three NT1 patients had not yet had their hypocretin values measured, but had cataplexy and were HLA-DQB1*0602-positive). Our study is the first study to report thinner cortex in the temporal poles and entorhinal cortex in patients compared to controls, but as previously mentioned several studies

[12, 13, 15, 18, 24] have implicated the superior temporal regions. The difference in findings could possibly be related to our patient sample being homogenous and well-characterized. It could also be related to most of the previous studies [12-14, 16-18, 20, 21, 24] using 1.5-T scanners except for three studies. [19, 23, 25] Another probable explanation could be that our study has almost twice the sample size ($n = 54$) as the largest previous study ($n=29$ narcolepsy patients) [12] investigating brain volume across a large number of brain regions, which reduces the uncertainty of the effect sizes and the risk of both false negatives and false positives. The largest previous study [12] did not report information about disease duration, medication and hypocretin deficiency status and it was unclear if both NT1 patients and NT2 patients were included, which also can provide an explanation for the differences in results.

Our patient population is largely H1N1-vaccinated which could potentially contribute to differences in findings from previous studies. It has since the 2009 H1N1-vaccinations been an ongoing discussion if the previously known sporadic NT1 and NT1 after H1N1-vaccination are exactly the same disease entity/phenotype, although most studies point in to the “one entity/phenotype” direction. [3, 55-57]

Comorbidities are frequently observed among patients with narcolepsy, [4] and this may have confounded the initial case-control comparisons. However, sensitivity analysis largely supported the main findings, suggesting that the group differences cannot be simply explained by known comorbid conditions.

In conclusion, compared to healthy controls, hypocretin deficient NT1 patients have thinner MRI-based cerebral cortex in several temporal brain regions, including bilateral STG, entorhinal cortex and temporal poles. Entorhinal cortex and temporal poles are involved in memory functions and STG play a role in speech and hallucinations. Thinner cortex in these regions have been implicated in schizophrenia and obstructive sleep apnea, diseases sharing common features with NT1. Although speculative, these findings may reflect secondary

effects of a primary loss/dysfunction of the hypocretin-producing neurons. Alternatively, the findings might be associated with the characteristic abnormal sleep-wake pattern in NT1 patients. Future longitudinal studies are needed to assess the clinical relevance and dynamics of the observed brain structural abnormalities.

Acknowledgments

A special thank you goes to Janita Vevelstad (nurse at the Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias (NevSom), Oslo University Hospital) and Rannveig Viste (nurse, molecular biologist and PhD-student at the Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias (NevSom), Oslo University Hospital) for being a part of the data collection and sleep scoring of polysomnography/multiple sleep latency tests. Furthermore, we would like to express our appreciation for Ranveig Østrem's (bioengineer at the Hormone Laboratory at Oslo University Hospital) work with the HLA-typing.

Funding:

S. K. H was partially funded by research support from the Norwegian Ministry of Health and Care Services. H.T.J was during data collection fully funded by the Norwegian Ministry of Health and Care Services and during data analyses by the Helse SØ grant (2019032). D. A was supported by the South-Eastern Norway Regional Health Authorities (2019107, 2020086). The European Union's Horizon 2020 Research and Innovation program (ERC StG, Grant # 802998), the Research Council of Norway (223273, 249795, 300767) and the South-Eastern Norway Regional Health Authority (2019101) was also part of funding this study.

Disclosure Statement

H.T.J reports no competing interests. D.A. reports no competing interests. I.A. received speaker's honorarium from Lundbeck. O.A.A. is a consultant for HealthLytix and has received speaker's honorarium from Lundbeck and Sunovion. A.S. reports no competing interests. P.M.T. reports no competing interests. L.T.W reports no competing interests. S.K.H have been lecturing about narcolepsy for UCB Pharma, AOP Orphan, Jazz Pharmaceuticals, Lundbeck AS, honorarium have been paid to Norwegian Centre of Expertise for Neurodevelopmental Disorders and Hypersomnias (NevSom). S.K.H. has received honorarium for being an expert consultant for the Norwegian state regarding narcolepsy and Pandemrix.

References

1. Bassetti, C.L.A., et al., *Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment*. Nat Rev Neurol, 2019. **15**(9): p. 519-539.
2. Heier, M.S., et al., *Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A*. Sleep Med, 2013. **14**(9): p. 867-71.
3. Sarkanen, T.O., et al., *Incidence of narcolepsy after H1N1 influenza and vaccinations: Systematic review and meta-analysis*. Sleep Med Rev, 2018. **38**: p. 177-186.
4. Kornum, B.R., et al., *Narcolepsy*. Nat Rev Dis Primers, 2017. **3**: p. 16100.
5. Peyron, C., et al., *A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains*. Nat Med, 2000. **6**(9): p. 991-7.
6. Thannickal, T.C., et al., *Reduced number of hypocretin neurons in human narcolepsy*. Neuron, 2000. **27**(3): p. 469-74.
7. Peyron, C., et al., *Neurons containing hypocretin (orexin) project to multiple neuronal systems*. J Neurosci, 1998. **18**(23): p. 9996-10015.
8. John, J., et al., *Greatly increased numbers of histamine cells in human narcolepsy with cataplexy*. Ann Neurol, 2013. **74**(6): p. 786-93.
9. Valko, P.O., et al., *Increase of histaminergic tuberomammillary neurons in narcolepsy*. Ann Neurol, 2013. **74**(6): p. 794-804.
10. Shan, L., Y. Dauvilliers, and J.M. Siegel, *Interactions of the histamine and hypocretin systems in CNS disorders*. Nat Rev Neurol, 2015. **11**(7): p. 401-13.
11. Wada, M., et al., *Neuroimaging correlates of narcolepsy with cataplexy: A systematic review*. Neurosci Res, 2019. **142**: p. 16-29.
12. Draganski, B., et al., *Hypothalamic gray matter changes in narcoleptic patients*. Nat Med, 2002. **8**(11): p. 1186-8.
13. Kaufmann, C., et al., *Reduced cortical gray matter in narcolepsy: preliminary findings with voxel-based morphometry*. Neurology, 2002. **58**(12): p. 1852-5.
14. Overeem, S., et al., *Voxel-based morphometry in hypocretin-deficient narcolepsy*. Sleep, 2003. **26**(1): p. 44-6.
15. Weng, H.H., et al., *Gray matter atrophy in narcolepsy: An activation likelihood estimation meta-analysis*. Neurosci Biobehav Rev, 2015. **59**: p. 53-63.
16. Brabec, J., et al., *Volume of the amygdala is reduced in patients with narcolepsy - a structural MRI study*. Neuro Endocrinol Lett, 2011. **32**(5): p. 652-6.
17. Brenneis, C., et al., *Voxel-based morphometry in narcolepsy*. Sleep Med, 2005. **6**(6): p. 531-6.
18. Joo, E.Y., et al., *Gray matter concentration abnormality in brains of narcolepsy patients*. Korean J Radiol, 2009. **10**(6): p. 552-8.
19. Kim, S.J., et al., *Gray matter deficits in young adults with narcolepsy*. Acta Neurol Scand, 2009. **119**(1): p. 61-7.
20. Buskova, J., et al., *Reduced hypothalamic gray matter in narcolepsy with cataplexy*. Neuro Endocrinol Lett, 2006. **27**(6): p. 769-72.
21. Joo, E.Y., et al., *Analysis of cortical thickness in narcolepsy patients with cataplexy*. Sleep, 2011. **34**(10): p. 1357-64.
22. Joo, E.Y., et al., *Hippocampal volume and memory in narcoleptics with cataplexy*. Sleep Med, 2012. **13**(4): p. 396-401.
23. Schaer, M., et al., *Cortical morphometry in narcolepsy with cataplexy*. J Sleep Res, 2012. **21**(5): p. 487-94.

24. Scherfler, C., et al., *White and gray matter abnormalities in narcolepsy with cataplexy*. *Sleep*, 2012. **35**(3): p. 345-51.
25. Kim, H., et al., *Morphological alterations in amygdalo-hippocampal substructures in narcolepsy patients with cataplexy*. *Brain Imaging Behav*, 2016. **10**(4): p. 984-994.
26. Nemcova, V., et al., *Hippocampal but not amygdalar volume loss in narcolepsy with cataplexy*. *Neuro Endocrinol Lett*, 2015. **36**(7): p. 682-8.
27. American Academy of Sleep Medicine(AASM), *International Classification of Sleep Disorders (ICSD) 3ed*. 2014.
28. Anic-Labat, S., et al., *Validation of a cataplexy questionnaire in 983 sleep-disorders patients*. *Sleep*, 1999. **22**(1): p. 77-87.
29. Knudsen, S., et al., *Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population*. *Sleep*, 2010. **33**(2): p. 169-76.
30. Heier, M.S., et al., *CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway*. *Sleep*, 2007. **30**(8): p. 969-73.
31. Fischl, B., *FreeSurfer*. *Neuroimage*, 2012. **62**(2): p. 774-81.
32. Rosen, A.F.G., et al., *Quantitative assessment of structural image quality*. *Neuroimage*, 2018. **169**: p. 407-418.
33. Laboratory for Computational Neuroimaging. *FreeSurfer*. 2022 02.06.2022 [cited 2022 05.07]; Available from: <https://surfer.nmr.mgh.harvard.edu/fswiki/FreeSurferWiki>.
34. Winkler, A.M., et al., *Permutation inference for the general linear model*. *Neuroimage*, 2014. **92**: p. 381-97.
35. Winkler, A.M., et al., *Multi-level block permutation*. *Neuroimage*, 2015. **123**: p. 253-68.
36. Analysis Group FMRIB. *PALM*. 2020 08.06.2020 [cited 2022 05.07]; Available from: <https://fsl.fmrib.ox.ac.uk/fsl/fslwiki/PALM>.
37. Benjamini, Y. and Y. Hochberg, *Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing*. *Journal of the Royal Statistical Society: Series B (Methodological)*, 1995. **57**(1): p. 289-300.
38. Yi, H.G., M.K. Leonard, and E.F. Chang, *The Encoding of Speech Sounds in the Superior Temporal Gyrus*. *Neuron*, 2019. **102**(6): p. 1096-1110.
39. Robson, H., et al., *Revealing and quantifying the impaired phonological analysis underpinning impaired comprehension in Wernicke's aphasia*. *Neuropsychologia*, 2012. **50**(2): p. 276-88.
40. Bandeira, I.D., et al., *Analysis of the superior temporal gyrus as a possible biomarker in schizophrenia using voxel-based morphometry of the brain magnetic resonance imaging: a comprehensive review*. *CNS Spectr*, 2021. **26**(4): p. 319-325.
41. Kasai, K., et al., *Progressive decrease of left superior temporal gyrus gray matter volume in patients with first-episode schizophrenia*. *Am J Psychiatry*, 2003. **160**(1): p. 156-64.
42. Hanin, C., et al., *Narcolepsy and psychosis: A systematic review*. *Acta Psychiatr Scand*, 2021. **144**(1): p. 28-41.
43. Park, C.H., et al., *Sleep disturbance-related depressive symptom and brain volume reduction in shift-working nurses*. *Sci Rep*, 2020. **10**(1): p. 9100.
44. Macey, P.M., et al., *Obstructive sleep apnea and cortical thickness in females and males*. *PLoS One*, 2018. **13**(3): p. e0193854.
45. Landi, S.M., et al., *A fast link between face perception and memory in the temporal pole*. *Science*, 2021. **373**(6554): p. 581-585.

46. Herlin, B., V. Navarro, and S. Dupont, *The temporal pole: From anatomy to function-A literature appraisal*. J Chem Neuroanat, 2021. **113**: p. 101925.
47. van Erp, T.G.M., et al., *Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium*. Biol Psychiatry, 2018. **84**(9): p. 644-654.
48. Lee, S.H., et al., *Initial and Progressive Gray Matter Abnormalities in Insular Gyrus and Temporal Pole in First-Episode Schizophrenia Contrasted With First-Episode Affective Psychosis*. Schizophr Bull, 2016. **42**(3): p. 790-801.
49. Gerlei, K.Z., et al., *Deep entorhinal cortex: from circuit organization to spatial cognition and memory*. Trends Neurosci, 2021. **44**(11): p. 876-887.
50. Sosa, M. and L.M. Giocomo, *Navigating for reward*. Nat Rev Neurosci, 2021. **22**(8): p. 472-487.
51. Sugar, J. and M.B. Moser, *Episodic memory: Neuronal codes for what, where, and when*. Hippocampus, 2019. **29**(12): p. 1190-1205.
52. Canessa, N., et al., *Obstructive sleep apnea: brain structural changes and neurocognitive function before and after treatment*. Am J Respir Crit Care Med, 2011. **183**(10): p. 1419-26.
53. Strauss, M., et al., *Order matters: sleep spindles contribute to memory consolidation only when followed by rapid-eye-movement sleep*. Sleep, 2022. **45**(4).
54. Filardi, M., et al., *Cognitive dysfunction in central disorders of hypersomnolence: A systematic review*. Sleep Med Rev, 2021. **59**: p. 101510.
55. Alakuijala, A., T. Sarkanen, and M. Partinen, *Polysomnographic and actigraphic characteristics of patients with H1N1-vaccine-related and sporadic narcolepsy*. Sleep Med, 2015. **16**(1): p. 39-44.
56. Juvodden, H.T., et al., *HLA and sleep parameter associations in post-H1N1 narcolepsy type 1 patients and first-degree relatives*. Sleep, 2020. **43**(3).
57. Szakács, A., N. Darin, and T. Hallböök, *Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination*. Neurology, 2013. **80**(14): p. 1315-21.

All regions




Figure 1. All tested cortical regions

Effect sizes are shown for the thickness measures obtained for 34 bilateral cortical regions.

The brain regions are based on the Desikan-Killiany atlas as included in FreeSurfer. [31]

Corpus callosum was not a part of this analysis.

Significant regions




Figure 2. All significant regions

Effect sizes for the three bilateral cortical regions (superior temporal gyrus, entorhinal cortex and temporal poles) where patients had significantly thinner cortex than healthy controls after permutation testing and FDR correction. The brain regions are based on the Desikan-Killiany atlas as included in FreeSurfer. [31]

Table 1. Demographic and clinical data

	Narcolepsy type 1 patients (n = 54)	Healthy controls (n = 114)
Sex (female), n (%)	39 (72.2)	77 (67.5)
Age (years), mean \pm SD	21.8 \pm 11.0	23.2 \pm 9.0
Age at disease onset (years), mean \pm SD	16.1 \pm 10.8	N/A
Disease duration (years), mean \pm SD	5.8 \pm 1.4	N/A
H1N1-vaccinated, n (%)	48 (88.9)*	N/A
Cataplexy, n (%)	53 (98.1)	N/A
HLA-DQB1*06:02-positivity, n (%)	54 (100)	N/A
CSF hypocretin $1 \leq 1/3$ level in normal population	51 3 -N/A	N/A
AHI ≥ 5	5 (9.3)	N/A
Hypnagogic hallucinations, n (%)	46 (85.2)	N/A
Sleep paralysis, n (%)	38 (70.4)	N/A

*Disease onset was reclassified to being before the H1N1-vaccination for three typical narcolepsy type 1 patients after additionally acquired information during/after study inclusion.

AHI: Apnea–Hypopnea Index, N/A: not available, SD: standard deviation.

Table 2. Uncorrected mean bilateral cortical thickness

	NT1 patients (mean \pm SD)	Controls (mean \pm SD)	p	Cohen's d
Temporal poles	3.23 \pm 0.28	3.40 \pm 0.29	0.00080**	0.68
Entorhinal	3.04 \pm 0.23	3.18 \pm 0.25	0.0018**	0.60
Superior temporal	2.82 \pm 0.13	2.87 \pm 0.13	0.0020**	0.60
Middle temporal	2.82 \pm 0.12	2.86 \pm 0.13	0.0088*	0.50
Rostral middle frontal	2.36 \pm 0.10	2.39 \pm 0.10	0.009*	0.49
Superior frontal	2.78 \pm 0.12	2.81 \pm 0.14	0.029*	0.41
Postcentral	2.12 \pm 0.11	2.16 \pm 0.12	0.043*	0.38
Banks of the STS	2.60 \pm 0.15	2.61 \pm 0.14	0.36	0,17
Caudal middle frontal	2.61 \pm 0.13	2.63 \pm 0.11	0.061	0.35
Cuneus	2.06 \pm 0.13	2.06 \pm 0.12	0.76	0.055
Insula	3.08 \pm 0.16	3.06 \pm 0.13	0.72	0.070
Inferior temporal	2.74 \pm 0.15	2.74 \pm 0.12	0.87	0.031
Caudal anterior cingulate	2.49 \pm 0.17	2.48 \pm 0.15	0.84	0.039
Posterior cingulate	2.50 \pm 0.13	2.51 \pm 0.12	0.38	0.17
Fusiform	2.80 \pm 0.13	2.80 \pm 0.11	0.60	0.099
Inferior parietal	2.45 \pm 0.11	2.47 \pm 0.12	0.12	0.29
Isthmus cingulate	2.45 \pm 0.16	2.42 \pm 0.14	0.27	0.22
Lateral occipital	2.18 \pm 0.09	2.18 \pm 0.11	0.87	0.028
Lateral orbitofrontal	2.56 \pm 0.14	2.57 \pm 0.11	0.41	0.15
Lingual	2.24 \pm 0.13	2.22 \pm 0.12	0.72	0.066
Medial orbitofrontal	2.46 \pm 0.13	2.44 \pm 0.10	0.38	0.17

Parahippocampal	2.83 ± 0.17	2.85 ± 0.20	0.43	0.15
Paracentral	2.56 ± 0.13	2.58 ± 0.12	0.24	0.22
Parsopercularis	2.67 ± 0.12	2.68 ± 0.12	0.29	0.20
Parsorbitalis	2.72 ± 0.14	2.74 ± 0.16	0.14	0.27
Parstriangularis	2.52 ± 0.13	2.55 ± 0.12	0.075	0.34
Pericalcarine	1.82 ± 0.13	1.82 ± 0.15	0.98	0.0043
Precentral	2.57 ± 0.12	2.59 ± 0.11	0.15	0.27
Precuneus	2.53 ± 0.11	2.53 ± 0.11	0.76	0.058
Rostral anterior cingulate	2.89 ± 0.18	2.87 ± 0.15	0.74	0.064
Superior parietal	2.29 ± 0.09	2.29 ± 0.10	0.73	0.068
Supramarginal	2.53 ± 0.13	2.55 ± 0.13	0.25	0.22
Frontalpole	2.66 ± 0.19	2.69 ± 0.24	0.20	0.24
Transverse temporal	2.55 ± 0.20	2.58 ± 0.17	0.12	0.29

Thickness(mm) is not corrected for age or sex. Two-tailed p-values and the Cohen's d are from the analysis with models including correction for age and sex. NT1 patients: narcolepsy type 1 patients, SD: standard deviation, STS: Superior temporal sulcus. *Significant after permutation testing, ** significant after permutation testing and correction for multiple testing with the Benjamini-Hochberg-procedure.

Table 3. Uncorrected mean bilateral volume

	NT1 patients (mean \pm SD)	Controls (mean \pm SD)	p	Cohen's d
Cortex	523304.1 \pm 57940.9	539223.5 \pm 55584.0	0.03*	0.43
Total gray vol	704082.7 \pm 69488.9	720001.5 \pm 66017.1	0.059	0.37
Subcort gray vol	60392.2 \pm 5203.1	61043.7 \pm 5047.2	0.41	0.16
Caudate	7632.9 \pm 1042.0	7770.7 \pm 922.1	0.79	0.065
Pallidum	4020.5 \pm 387.4	4022.7 \pm 420.1	0.29	0.26
Putamen	10514.7 \pm 1143.7	10608.1 \pm 1112.9	0.95	0.015
Brainstem	20839.0 \pm 2141.5	20914.1 \pm 2670.2	0.089	0.42
Ventral DC	7946.2 \pm 790.1	8026.0 \pm 844.3	0.39	0.21
Cerebellum Cortex	119994.3 \pm 12222.7	119278.5 \pm 11396.6	0.14	0.36
Amygdala	3302.9 \pm 369.2	3395.5 \pm 355.5	0.38	0.21
Hippocampus	8453.0 \pm 756.4	8565.9 \pm 762.5	0.71	0.090
Thalamus	15693.0 \pm 1539.3	15898.6 \pm 1546.9	0.70	0.096
Accumbens area	1204.9 \pm 187.6	1242.3 \pm 208.0	0.48	0.18

Volumes(mm³) are not corrected for age, sex or intracranial volume. Two-tailed p-values and the Cohen's d are from the analysis of models including correction for age and sex for global measures and age, sex and intracranial volume (ICV) for regional volume measures. SD: standard deviation. *Significant after permutation testing